Is Klotho Neurosciences, Inc. (KLTO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 0.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.8% / 33% | 0.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 11.1% / 33% | 2.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 0.8% / 33% | 0.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 11.1% / 33% | 2.6% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -198.3% | |
| Return on Assets (ROA) | -71.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Total Debt | $271,753 |
| Current Ratio | 83.7 |
| Total Assets | $2M |
Price & Trading
| Last Close | $0.52 |
| 50-Day MA | $0.33 |
| 200-Day MA | $0.65 |
| Avg Volume | 2.4M |
| Beta | 2.2 |
|
52-Week Range
$0.11
| |
About Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Klotho Neurosciences, Inc. (KLTO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Klotho Neurosciences, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Klotho Neurosciences, Inc.'s debt ratio?
Klotho Neurosciences, Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.1%.
What are Klotho Neurosciences, Inc.'s key financial metrics?
Klotho Neurosciences, Inc. has a market capitalization of $57M. Return on equity stands at -198.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.